Lercapril

Enalapril maleate / lercanidipine hydrochloride, the active ingredient in Lercapril, is an ACE inhibitor and calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure and improving cardiovascular outcomes.

GNH USA supplies Lercapril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercapril is employed in the management of elevated arterial pressure, targeting both the renin‑angiotensin system and vascular smooth‑muscle tone to control hypertension.

Hypertension (essential or secondary): provides combined ACE inhibition and calcium‑channel blockade, resulting in consistent reduction of systolic and diastolic blood pressure, decreased peripheral vascular resistance, and a favorable impact on long‑term cardiovascular risk.

Lercapril may cause a range of adverse reactions, some of which are relatively frequent while others are rare but serious.

Common Side Effects: - Cough - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing - Fatigue

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension - Acute kidney injury or worsening renal function - Hepatic dysfunction - Myocardial infarction or unstable angina - Life‑threatening arrhythmias

Before initiating Lercapril, clinicians should consider several safety aspects. - Renal function monitoring: assess serum creatinine and eGFR regularly. - Electrolyte balance: watch potassium levels, especially if combined with potassium‑sparing agents. - History of angioedema: avoid use in patients with prior ACE‑inhibitor‑related swelling. - Hepatic impairment: use with caution and adjust dose if needed. - Concomitant potassium supplements or salt substitutes: monitor for hyperkalaemia. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Lercapril can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - ARBs or direct renin inhibitors (e.g., aliskiren in diabetic patients): risk of additive renal impairment and hyperkalaemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can raise lercanidipine concentrations. - Other antihypertensives (beta‑blockers, diuretics): may enhance blood‑pressure lowering, requiring dose adjustments.